AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Biospace

Published November 10, 2026 · Updated November 11, 2026

BIO pitches US plan to beat China in biotech 'space race' - BioSpace

Read the full story at Biospace

Psychedelics · Delix raises $100M to advance at-home psychedelic without hallucinogenic effects. November 10, 2026. ·. 2 min read. ·. Tristan Manalac.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic biotech